EIM
DNLI icon

Essex Investment Management’s Denali Therapeutics DNLI Stock Holding History

Essex Investment Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-8,130
Closed -$189K – 491
2019
Q1 		$189K Sell
8,130
-690
-8% -$14.4K 0.03% 349
2018
Q4 		$182K Buy
+8,820
New +$160K 0.03% 346

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Essex Investment Management's DNLI Position: Q2 2019 in Review

Essex Investment Management sold out of Denali Therapeutics (DNLI) in Q2 2019, closing a stake of 8,130 shares — an estimated $189K sold.

Essex Investment Management first reported a position in DNLI in Q4 2018 and held it in 2 quarters. The position peaked at $189K in Q1 2019. 114 funds tracked by Wall St. Rank hold DNLI as of Q2 2019.

  • Essex Investment Management reported no remaining Denali Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Essex Investment Management sold 8,130 Denali Therapeutics shares in Q2 2019, an estimated $189K.
  • Essex Investment Management first reported a position in Denali Therapeutics in Q4 2018 and held it in 2 quarters.
  • Essex Investment Management's Denali Therapeutics position peaked at $189K in Q1 2019.
  • 114 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2019.

Based on Essex Investment Management's 13F filing for Q2 2019, filed 15 Aug 2019.